Evaluating the impact of cannabis use on thalamic connectivity in youth at clinical high risk of psychosis

BMC Psychiatry

Volumn 15, Issue 1, 2015, Pages

  Buchy, Lisa ^a   Cannon, Tyrone D ^b   Anticevic, Alan ^c   Lyngberg, Kristina ^d   Cadenhead, Kristin S ^e   Cornblatt, Barbara A ^f   McGlashan, Thomas H ^c   Perkins, Diana O ^g   Seidman, Larry J ^h   Tsuang, Ming T ^f   Walker, Elaine F ⁱ   Woods, Scott W ^c   Bearden, Carrie E ^j   Mathalon, Daniel H ^k   Addington, Jean ^a,d  

^a UNIVERSITY OF CALGARY   (Canada)

^b YALE UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f ZUCKER HILLSIDE HOSPITAL   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ EMORY UNIVERSITY   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Cannabis; Clinical high risk; Functional connectivity; Psychosis; Resting state functional magnetic resonance imaging; Schizophrenia; Thalamus

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANNABIS USE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FUNCTIONAL CONNECTIVITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GRAY MATTER; HIGH RISK PATIENT; HUMAN; LEFT HEMISPHERE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MOTOR CORTEX; ONSET AGE; PREFRONTAL CORTEX; PSYCHOSIS; SENSORY CORTEX; SEX DIFFERENCE; THALAMUS; ADVERSE EFFECTS; ANALYSIS OF VARIANCE; BRAIN MAPPING; CANNABIS SMOKING; CASE CONTROL STUDY; CLINICAL TRIAL; DRUG EFFECTS; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHYSIOLOGY; PRODROMAL SYMPTOM; PSYCHOTIC DISORDERS; RISK FACTOR; SCHIZOPHRENIA; YOUNG ADULT;

ADOLESCENT; AGE OF ONSET; ANALYSIS OF VARIANCE; BRAIN MAPPING; CASE-CONTROL STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MARIJUANA SMOKING; MOTOR CORTEX; PRODROMAL SYMPTOMS; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA; THALAMUS; YOUNG ADULT;

EID: 84946429819     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-015-0656-x     Document Type: Article

References (50)

1. Stephan KE, Baldeweg T, Friston KJ. Synaptic plasticity and dysconnection in schizophrenia. Biol Psychiatry. 2006;59(10):929-39.
2. Woodward ND, Karbasforoushan H, Heckers S. Thalamocortical dysconnectivity in schizophrenia. Am J Psychiatry. 2012;169(10):1092-9.
3. Anticevic A, Cole MW, Repovs G, Murray JD, Brumbaugh MS, Winkler AM, et al. Characterizing Thalamo-Cortical Disturbances in Schizophrenia and Bipolar Illness. Cereb Cortex. 2013;24(12):3116-30.
4. Collin G, HulshoffPol HE, Haijma SV, Cahn W, Kahn RS, van den Heuvel MP. Impaired cerebellar functional connectivity in schizophrenia patients and their healthy siblings. Frontiers in Psychiatry. 2011;2:73.
5. Skudlarski P, Jagannathan K, Anderson K, Stevens MC, Calhoun VD, Skudlarska BA, et al. Brain connectivity is not only lower but different in schizophrenia: a combined anatomical and functional approach. Biol Psychiatry. 2010;68(1):61-9.
6. Klingner CM, Langbein K, Dietzek M, Smesny S, Witte OW, Sauer H, et al. Thalamocortical connectivity during resting state in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2014;264(2):111-9.
7. Anticevic A, Haut K, Murray JD, Repovs G, Yang G, Diehl C, et al. Thalamic Dysconnectivity is Associated with Conversion to Psychosis in Youth at Elevated Clinical Risk. JAMA Psychiatry. 2015;72(9):882-91.
8. Addington J, Case N, Saleem MM, Auther AM, Cornblatt BA, Cadenhead KS. Substance use in clinical high risk for psychosis: a review of the literature. Early Interv Psychiatry. 2014;8(2):104-12.
9. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319-28.
10. Kuepper R, van Os J, Lieb R, Wittchen HU, Hofler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ. 2011;342:d738.
11. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 2012;69(3):220-9.
12. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-Omethyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005;57(10):1117-27.
13. Buchy L, Cadenhead KS, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, et al. Substance Use in Individuals at Clinical High Risk of Psychosis. Psychological Medicine. in press
14. Valmaggia LR, Day FL, Jones C, Bissoli S, Pugh C, Hall D, et al. Cannabis use and transition to psychosis in people at ultra-high risk. Psychol Med. 2014;44(12):2503-12.
15. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325(7374):1212-3.
16. Welch KA, McIntosh AM, Job DE, Whalley HC, Moorhead TW, Hall J, et al. The impact of substance use on brain structure in people at high risk of developing schizophrenia. Schizophr Bull. 2011;37(5):1066-76.
17. Welch KA, Stanfield AC, McIntosh AM, Whalley HC, Job DE, Moorhead TW, et al. Impact of cannabis use on thalamic volume in people at familial high risk of schizophrenia. Br J Psychiatry. 2011;199(5):386-90.
18. Eggan SM, Lewis DA. Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb Cortex. 2007;17(1):175-91.
19. Anticevic A. Examining risk for psychosis onset and progression via functional connectivity neuroimaging markers. Biological Psychiatry. 2015;77(9S): 149S.
20. Addington J, Cadenhead KS, Cornblatt BA, Mathalon DH, McGlashan TH, Perkins DO, et al. North American Prodrome Longitudinal Study (NAPLS 2): overview and recruitment. Schizophr Res. 2012;142(1-3):77-82.
21. McGlashan TH, Walsh BC, Woods SW. The psychosis risk syndrome: Handbook for diagnosis and follow-up. New York: Oxford University Press; 2010.
22. Drake RE, Mueser K, McHugo G. Clinical Rating Scales. In: Sederer L, Dickey B, editors. Outcomes assessment in clinical practice. Baltimore: Williams and Wilkins; 1996. p. 113-6.
23. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ. 2005;330(7481):11.
24. Cannon TD, Sun F, McEwen SJ, Papademetris X, He G, van Erp TG, et al. Reliability of neuroanatomical measurements in a multisite longitudinal study of youth at risk for psychosis. Hum Brain Mapp. 2014;35(5):2424-34.
25. Anticevic A, Repovs G, Barch DM. Resisting emotional interference: brain regions facilitating working memory performance during negative distraction. Cogn Affect Behav Neurosci. 2010;10(2):159-73.
26. Anticevic A, Repovs G, Krystal JH, Barch DM. A broken filter: Prefrontal functional connectivity abnormalities in schizophrenia during working memory interference. Schizophrenia Bulletin 2012. Epub ahead of print.
27. Repovs G, Csernansky JG, Barch DM. Brain network connectivity in individuals with schizophrenia and their siblings. Biol Psychiatry. 2011;69(10):967-73.
28. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33(3):341-55.
29. Fischl B, Salat DH, van der Kouwe AJ, Makris N, Segonne F, Quinn BT, et al. Sequence-independent segmentation of magnetic resonance images. Neuroimage. 2004;23 Suppl 1:S69-84.
30. Anticevic A, Cole MW, Repovs G, Murray JD, Brumbaugh MS, Winkler AM, et al. Characterizing Thalamo-Cortical Disturbances in Schizophrenia and Bipolar Illness. Cereb Cortex. 2014;24(12): 3116-30.
31. Stone JM, Bhattacharyya S, Barker GJ, McGuire PK. Substance use and regional gray matter volume in individuals at high risk of psychosis. Eur Neuropsychopharmacol. 2012;22(2):114-22.
32. James A, Hough M, James S, Winmill L, Burge L, Nijhawan S, et al. Greater white and grey matter changes associated with early cannabis use in adolescent-onset schizophrenia (AOS). Schizophr Res. 2011;128(1-3):91-7.
33. Ashton JC, Appleton I, Darlington CL, Smith PF. Immunohistochemical localization of cannabinoid CB1 receptor in inhibitory interneurons in the cerebellum. Cerebellum. 2004;3(4):222-6.
34. Heng L, Beverley JA, Steiner H, Tseng KY. Differential developmental trajectories for CB1 cannabinoid receptor expression in limbic/associative and sensorimotor cortical areas. Synapse. 2011;65(4):278-86.
35. Kumra S, Robinson P, Tambyraja R, Jensen D, Schimunek C, Houri A, et al. Parietal lobe volume deficits in adolescents with schizophrenia and adolescents with cannabis use disorders. J Am Acad Child Adolesc Psychiatry. 2012;51(2):171-80.
36. Bangalore SS, Prasad KM, Montrose DM, Goradia DD, Diwadkar VA, Keshavan MS. Cannabis use and brain structural alterations in first episode schizophrenia-a region of interest, voxel based morphometric study. Schizophr Res. 2008;99(1-3):1-6.
37. Epstein KA, Kumra S. Altered cortical maturation in adolescent cannabis users with and without schizophrenia. Schizophr Res. 2015;162(1-3):143-52.
38. Habets P, Marcelis M, Gronenschild E, Drukker M, van Os J, Genetic R, et al. Reduced cortical thickness as an outcome of differential sensitivity to environmental risks in schizophrenia. Biol Psychiatry. 2011;69(5):487-94.
39. Cohen M, Rasser PE, Peck G, Carr VJ, Ward PB, Thompson PM, et al. Cerebellar grey-matter deficits, cannabis use and first-episode schizophrenia in adolescents and young adults. Int J Neuropsychopharmacol. 2012;15(3):297-307.
40. Rapp C, Walter A, Studerus E, Bugra H, Tamagni C, Rothlisberger M, et al. Cannabis use and brain structural alterations of the cingulate cortex in early psychosis. Psychiatry Res. 2013;214(2):102-8.
41. Welch KA, Moorhead TW, McIntosh AM, Owens DG, Johnstone EC, Lawrie SM. Tensor-based morphometry of cannabis use on brain structure in individuals at elevated genetic risk of schizophrenia. Psychol Med. 2013;43(10):2087-96.
42. Rais M, van Haren NE, Cahn W, Schnack HG, Lepage C, Collins L, et al. Cannabis use and progressive cortical thickness loss in areas rich in CB1 receptors during the first five years of schizophrenia. Eur Neuropsychopharmacol. 2010;20(12):855-65.
43. Rais M, Cahn W, Van Haren N, Schnack H, Caspers E, HulshoffPol H, et al. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am J Psychiatry. 2008;165(4):490-6.
44. Smith MJ, Cobia DJ, Wang L, Alpert KI, Cronenwett WJ, Goldman MB, et al. Cannabis-related working memory deficits and associated subcortical morphological differences in healthy individuals and schizophrenia subjects. Schizophr Bull. 2014;40(2):287-99.
45. Fornito A, Harrison BJ, Goodby E, Dean A, Ooi C, Nathan PJ, et al. Functional dysconnectivity of corticostriatal circuitry as a risk phenotype for psychosis. JAMA Psychiatry. 2013;70(11):1143-51.
46. Palaniyappan L, Simmonite M, White TP, Liddle EB, Liddle PF. Neural primacy of the salience processing system in schizophrenia. Neuron. 2013;79(4):814-28.
47. Baker JT, Holmes AJ, Masters GA, Yeo BT, Krienen F, Buckner RL, et al. Disruption of cortical association networks in schizophrenia and psychotic bipolar disorder. JAMA Psychiatry. 2014;71(2):109-18.
48. Whitfield-Gabrieli S, Thermenos HW, Milanovic S, Tsuang MT, Faraone SV, McCarley RW, et al. Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc Natl Acad Sci U S A. 2009;106(4):1279-84.
49. Whitfield-Gabrieli S, Moran JM, Nieto-Castanon A, Triantafyllou C, Saxe R, Gabrieli JD. Associations and dissociations between default and self-reference networks in the human brain. Neuroimage. 2011;55(1):225-32.
50. Kuepper R, Ceccarini J, Lataster J, van Os J, van Kroonenburgh M, van Gerven JM, et al. Delta-9-tetrahydrocannabinol-induced dopamine release as a function of psychosis risk: 18F-fallypride positron emission tomography study. PLoS One. 2013;8(7):e70378.